Activin and Inhibin

(+)-Oxypeucedanin methanolate (compound 9) is a natural compound with inhibitory effect on prostaglandin E2 production.

(+)-Oxypeucedanin methanolate (compound 9) is a natural compound with inhibitory effect on prostaglandin E2 production.

(+)-Penbutolol is a β-adrenoceptor antagonist, with an IC 50 of 0.74 μM (+)-Penbutolol is an optical isomer of l-penbutolol with Na + channel-blocking action .In Vitro(+)-penbutolol on the [Ca 2+ ] i -increase induced by LPC is

(+)-Penbutolol is a β-adrenoceptor antagonist, with an IC 50 of 0.74 μM (+)-Penbutolol is an optical isomer of l-penbutolol with Na + channel-blocking action .In Vitro(+)-penbutolol on the [Ca 2+ ] i -increase induced by LPC is

(+)-Penbutolol is a β-adrenoceptor antagonist, with an IC 50 of 0.74 μM (+)-Penbutolol is an optical isomer of l-penbutolol with Na + channel-blocking action .In Vitro(+)-penbutolol on the [Ca 2+ ] i -increase induced by LPC is

(+)-Penbutolol is a β-adrenoceptor antagonist, with an IC 50 of 0.74 μM (+)-Penbutolol is an optical isomer of l-penbutolol with Na + channel-blocking action .In Vitro(+)-penbutolol on the [Ca 2+ ] i -increase induced by LPC is

(+)-Penbutolol is a β-adrenoceptor antagonist, with an IC 50 of 0.74 μM (+)-Penbutolol is an optical isomer of l-penbutolol with Na + channel-blocking action .In Vitro(+)-penbutolol on the [Ca 2+ ] i -increase induced by LPC is

(+)-Talarozole is a potent inhibitor of retinoic acid metabolism extracted from patent WO 1997049704 A1.Form:SolidIC50&amp: Target:retinoic acid.

(+)-Talarozole is a potent inhibitor of retinoic acid metabolism extracted from patent WO 1997049704 A1.Form:SolidIC50&amp: Target:retinoic acid.

(+)-Talarozole is a potent inhibitor of retinoic acid metabolism extracted from patent WO 1997049704 A1.Form:SolidIC50&amp: Target:retinoic acid.

(+)-Talarozole is a potent inhibitor of retinoic acid metabolism extracted from patent WO 1997049704 A1.Form:SolidIC50&amp: Target:retinoic acid.

(+)-Talarozole is a potent inhibitor of retinoic acid metabolism extracted from patent WO 1997049704 A1.IC50&amp: Target:retinoic acid.